Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.
It has been suggested that treatment with adequate dose titration of pegvisomant, a GH antagonist, up to a maximum of 40 mg daily, can achieve IGF-1 normalisation in virtually all patients with acromegaly. On the other hand, temozolomide (TMZ), an alkylating cytostatic agent, has been reported to reduce pituitary tumour size and hormone hypersecretion in a small number of aggressive pituitary macroadenomas. In this paper we report the case of a patient resistant to very high doses of pegvisomant used in combination with somatostatin analogs (SSA) and to TMZ therapy. The patient, initially a 22 year-old man with an invasive GH-secreting pituitary macroadenoma (IGF-1, 371% upper limit of normal), had active acromegaly despite a repeat transsphenoidal surgery followed by radiotherapy and SSA (octreotide 800 μg sc daily) (IGF-1, 262% ULN). In combination with SSA, pegvisomant was started at 20 mg daily and doses were titrated up to 60 mg daily. IGF-1 was moderately reduced and stabilized at 200% ULN after 1 year of treatment. Serum pegvisomant level was 30,500 ng/l, the denaturalized GHBP concentration 1,120 pM and the endogenous GH level was 220 μg/l. Pegvisomant was stopped and TMZ therapy was given for 5 cycles. However, the patient reported an increase of acromegaly symptoms and the serum IGF-1 was raised to the same level prior to pegvisomant therapy. Consequently, pegvisomant was tried again with doses up to 100 mg daily finally resulting in normalisation of serum IGF-1 level and improvement of acromegaly symptoms and patient well-being. We conclude that in some patients with severe acromegaly refractory to multimodal therapy, biochemical control may be difficult to attain with conventional doses of pegvisomant or TMZ therapy.
Morin
Emilie
E
Department of Endocrinolgy, CHUM Research Centre, Notre-Dame Hospital, 1560, rue Sherbrooke East, Montreal, QC, H2L 4M1, Canada.
Berthelet
France
F
Weisnagel
John
J
Bidlingmaier
Martin
M
Serri
Omar
O
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D000077204:Temozolomide; D016896:Treatment Outcome; D055815:Young Adult
D019382:Human Growth Hormone; D003606:Dacarbazine; C406545:pegvisomant; D000077204:Temozolomide
N Engl J Med. 2000 Nov 9;343(19):1350-4
11070098
J Clin Invest. 2009 Nov;119(11):3189-202
19884662
Neurosurgery. 2009 Apr;64(4):E773-4; discussion E774
19349807
J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8
18611977
Lancet. 2005 May 7-13;365(9471):1644-6
15885297
Pituitary. 2007;10(1):81-6
17285366
Hormones (Athens). 2009 Oct-Dec;8(4):303-6
20045804
Acta Neuropathol. 2008 Feb;115(2):261-2
17926052
BMC Endocr Disord. 2009 Oct 08;9:20
19814797
Hum Pathol. 2007 Jan;38(1):185-9
17056093
J Clin Endocrinol Metab. 1999 Aug;84(8):2759-65
10443675
J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5
16118335
Lancet. 2001 Nov 24;358(9295):1754-9
11734231
Eur J Endocrinol. 2009 Oct;161(4):631-7
19654234
Endocr Pathol. 2008 Summer;19(2):82-91
18629656
Clin Endocrinol (Oxf). 2006 Oct;65(4):552-3
16984254
Ann Endocrinol (Paris). 2009 Sep;70 Suppl 1:S12-9
19878763